Novolizer®: A Viewpoint by Peter Haidl

ISSN： 0012-6667

Source： Drugs, Vol.63, Iss.22, 2003-01, pp. : 2447-2448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ziconotide: A Viewpoint by Peter Staats

By Staats Peter

CNS Drugs, Vol. 20, Iss. 4, 2006-01 ,pp. : 339-341

Adis International

Access to resources Recommend Favorite

Brivudin: A Viewpoint by Peter Wutzler

By Peter Wutzler

Drugs, Vol. 64, Iss. 18, 2004-01 ,pp. : 2098-2099

Adis International

Access to resources Recommend Favorite

Esomeprazole: A Viewpoint by Peter Katelaris

By Katelaris P.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 330-331

Adis International

Access to resources Recommend Favorite

Intravenous Esomeprazole: A Viewpoint by Peter Bytzer

By Bytzer P.

Drugs, Vol. 64, Iss. 8, 2004-01 ,pp. : 883-883

Adis International

Access to resources Recommend Favorite

Atazanavir: A Viewpoint by Peter J. Piliero

By Piliero P.J.

Drugs, Vol. 63, Iss. 16, 2003-01 ,pp. : 1694-1695

Adis International

Access to resources Recommend Favorite